[Molecular Mechanism and Progression of Primary Resistance to EGFR-TKI
- Analysis of 2 Cases].

Zhongguo Fei Ai Za Zhi 2019 Jan;22(1):52-56

Department of Medical Oncology, Tianjin Medical University General Hospital, Tianjin 300052, China.

Tyrosine kinase inhibitor (TKI) have been proved to be effective in the treatment of advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) sensitive mutation, which is superior to chemotherapy. However, there are still some patients with sensitive mutations have primary drug resistance. It may be related to the coexistence of susceptible and resistant mutations of EGFR gene, downstream mutations of EGFR pathway, MET amplification and BIM deletion polymorphism. We present 2 cases of primary drug resistance and analyze the reasons.
.

Download full-text PDF

Source
http://dx.doi.org/10.3779/j.issn.1009-3419.2019.01.10DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348160PMC
January 2019
22 Reads

Publication Analysis

Top Keywords

primary drug
8
mutations egfr
8
drug resistance
8
chemotherapy patients
4
superior chemotherapy
4
patients sensitive
4
sensitive mutations
4
mutations primary
4
mutation superior
4
sensitive mutation
4
patients epidermal
4
nsclc patients
4
cancer nsclc
4
epidermal growth
4
growth factor
4
egfr sensitive
4
receptor egfr
4
resistance coexistence
4
coexistence susceptible
4
deletion polymorphism
4

Similar Publications